BiotechTube

RAP-219

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Epilepsy

Conditions

Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure

Trial Timeline

Dec 15, 2025 → Feb 3, 2028

NCT ID
NCT07219407

About RAP-219

RAP-219 is a phase 2 stage product being developed by Rapport Therapeutics for Focal Epilepsy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07219407. Target conditions include Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy.

What happened to similar drugs?

4 of 10 similar drugs in Focal Epilepsy were approved

Approved (4) Terminated (1) Active (6)
✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
✅DapagliflozinAstraZenecaApproved
✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved
🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3
🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07219407Phase 2Recruiting
NCT07046494Phase 2Recruiting
NCT06377930Phase 2Completed

Competing Products

20 competing products in Focal Epilepsy

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
35
DapagliflozinAstraZenecaApproved
43
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
35
CCX140-BAmgenPhase 2
27
PF-06730512PfizerPhase 2
27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
43
VX-147Vertex PharmaceuticalsPhase 2
35
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
VivaglobinCSLPhase 2
35
UCB0942UCBPhase 2
27
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
43
Brivaracetam + BrivaracetamUCBPhase 2
35
LacosamideUCBPhase 2
27
UCB0942 + UCB0942 + PlaceboUCBPhase 2
35
LacosamideUCBPre-clinical
26
ARGX-117ArgenxPhase 2
36